- Home
- BANX vs SPRO Comparison
BANX vs SPRO Comparison
Compare BANX & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANX
- SPRO
- Stock Information
- Founded
- BANX 2013
- SPRO 2013
- Country
- BANX United States
- SPRO United States
- Employees
- BANX N/A
- SPRO N/A
- Industry
- BANX Trusts Except Educational Religious and Charitable
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- BANX Finance
- SPRO Health Care
- Exchange
- BANX Nasdaq
- SPRO Nasdaq
- Market Cap
- BANX 146.9M
- SPRO 128.9M
- IPO Year
- BANX N/A
- SPRO 2017
- Fundamental
- Price
- BANX $21.16
- SPRO $2.43
- Analyst Decision
- BANX
- SPRO Buy
- Analyst Count
- BANX 0
- SPRO 4
- Target Price
- BANX N/A
- SPRO $5.00
- AVG Volume (30 Days)
- BANX 23.4K
- SPRO 1.2M
- Earning Date
- BANX 06-17-2025
- SPRO 11-13-2025
- Dividend Yield
- BANX 9.66%
- SPRO N/A
- EPS Growth
- BANX N/A
- SPRO N/A
- EPS
- BANX 2.35
- SPRO N/A
- Revenue
- BANX $29,467,794.00
- SPRO $48,576,000.00
- Revenue This Year
- BANX N/A
- SPRO N/A
- Revenue Next Year
- BANX N/A
- SPRO N/A
- P/E Ratio
- BANX $8.88
- SPRO N/A
- Revenue Growth
- BANX 2.73
- SPRO N/A
- 52 Week Low
- BANX $17.99
- SPRO $0.51
- 52 Week High
- BANX $21.67
- SPRO $3.22
- Technical
- Relative Strength Index (RSI)
- BANX 39.21
- SPRO 60.61
- Support Level
- BANX $21.06
- SPRO $2.16
- Resistance Level
- BANX $21.95
- SPRO $2.42
- Average True Range (ATR)
- BANX 0.28
- SPRO 0.12
- MACD
- BANX -0.08
- SPRO 0.00
- Stochastic Oscillator
- BANX 11.24
- SPRO 74.83
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.